

Stella M Davies

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3897929/publications.pdf>

Version: 2024-02-01

177
papers

4,523
citations

109264

35
h-index

138417

58
g-index

180
all docs

180
docs citations

180
times ranked

6280
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2018, 24, 1504-1506.	15.2	393
2	A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. <i>Blood Reviews</i> , 2015, 29, 191-204.	2.8	270
3	Ecuzumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 518-525.	2.0	218
4	Antibiotic-Induced Depletion of Anti-inflammatory Clostridia Is Associated with the Development of Graft-versus-Host Disease in Pediatric Stem Cell Transplantation Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 820-829.	2.0	130
5	Variable Ecuzumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 307-315.	2.0	125
6	Variable Clinical Presentation of Shwachman-Diamond Syndrome: Update from the North American Shwachman-Diamond Syndrome Registry. <i>Journal of Pediatrics</i> , 2014, 164, 866-870.	0.9	121
7	Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with ecuzumab. <i>Blood</i> , 2020, 135, 1049-1057.	0.6	103
8	Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. <i>Nature Communications</i> , 2021, 12, 1334.	5.8	103
9	Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1122-1127.	2.0	96
10	Antibiotic Exposure and Reduced Short Chain Fatty Acid Production after Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2418-2424.	2.0	85
11	Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. <i>Lancet Haematology</i> , 2020, 7, e238-e246.	2.2	73
12	Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. <i>Lancet Haematology</i> , 2017, 4, e325-e333.	2.2	72
13	Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. <i>Blood</i> , 2017, 129, 2308-2315.	0.6	71
14	Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. <i>Blood</i> , 2016, 127, 503-512.	0.6	69
15	Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1460-1470.	2.0	65
16	Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1994-2001.	2.0	63
17	Vitamin D Deficiency and Survival in Children after Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1627-1631.	2.0	59
18	Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1671-1677.	2.0	58

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis. <i>Blood</i> , 2016, 128, 2801-2801.	0.6	58
20	Numerical chromosomal changes and risk of development of myelodysplastic syndromeâ€“acute myeloid leukemia in patients with Fanconi anemia. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 180-186.	1.0	53
21	Adherence to outpatient oral medication regimens in adolescent hematopoietic stem cell transplant recipients. <i>European Journal of Oncology Nursing</i> , 2014, 18, 140-144.	0.9	52
22	Abnormal Echocardiography 7ÂDays after Stem Cell Transplantation May Be an Early Indicator of Thrombotic Microangiopathy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 113-118.	2.0	52
23	Outcomes of Donor Lymphocyte Infusion for Treatment of Mixed Donor Chimerism after a Reduced-Intensity Preparative Regimen for Pediatric Patients with Nonmalignant Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 288-292.	2.0	50
24	ST2 and Endothelial Injury as a Link between GVHD and Microangiopathy. <i>New England Journal of Medicine</i> , 2017, 376, 1189-1190.	13.9	50
25	Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. <i>Blood Advances</i> , 2018, 2, 2619-2628.	2.5	49
26	Bortezomib for Refractory Autoimmunity in Pediatrics. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1654-1659.	2.0	47
27	Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients withÂSLAM-Associated Protein Deficiency/X-linked Lymphoproliferative Disease Type 1. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1641-1645.	2.0	46
28	A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. <i>Blood Advances</i> , 2021, 5, 1-11.	2.5	46
29	Subsequent malignant neoplasms in survivors of childhood cancer: Childhood Cancer Survivor Study (CCSS) studies. <i>Pediatric Blood and Cancer</i> , 2007, 48, 727-730.	0.8	44
30	Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1337-1340.	2.0	42
31	High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 1311-1318.	1.3	41
32	Interferon-complement loop in transplant-associated thrombotic microangiopathy. <i>Blood Advances</i> , 2020, 4, 1166-1177.	2.5	41
33	Identifying Religious and/or Spiritual Perspectives of Adolescents and Young Adults Receiving Blood and Marrow Transplants: A Prospective Qualitative Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1242-1247.	2.0	38
34	The Natural History of BK Polyomavirus and the Host Immune Response After Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 71, 3044-3054.	2.9	38
35	Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1589-1596.	2.0	37
36	Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 482-486.	2.0	37

#	ARTICLE	IF	CITATIONS
37	Clinical Utility of Computed Tomography and Magnetic Resonance Imaging for Diagnosis of Posterior Reversible Encephalopathy Syndrome after Stem Cell Transplantation in Children and Adolescents. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2028-2032.	2.0	36
38	Rapid cycle development of a multifactorial intervention achieved sustained reductions in central line-associated bloodstream infections in haematology oncology units at a children's hospital: a time series analysis. <i>BMJ Quality and Safety</i> , 2016, 25, 633-643.	1.8	35
39	Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e280-e285.	2.0	35
40	Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy. <i>Journal of Clinical Immunology</i> , 2020, 40, 699-707.	2.0	35
41	Estimated versus Measured Glomerular Filtration Rate in Children before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2056-2061.	2.0	34
42	A challenging undertaking: Stem cell transplantation for immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 953-955.e4.	1.5	34
43	Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2024-2030.	2.0	33
44	Overcoming Pluripotent Stem Cell Dependence on the Repair of Endogenous DNA Damage. <i>Stem Cell Reports</i> , 2016, 6, 44-54.	2.3	29
45	Cytokine Profile of Engraftment Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 690-697.	2.0	28
46	A novel strategy for identifying early acute kidney injury in pediatric hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1453-1461.	1.3	28
47	Vitamin D Deficiency in Pediatric Hematopoietic Stem Cell Transplantation Patients Despite Both Standard and Aggressive Supplementation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1271-1274.	2.0	27
48	A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 418-422.	2.0	27
49	Variants in <i>BAK1</i> , <i>SPRY4</i> and <i>GAB2</i> are associated with pediatric germ cell tumors: A report from the children's oncology group. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 548-558.	1.5	27
50	Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary. <i>Annals of the American Thoracic Society</i> , 2021, 18, 381-394.	1.5	26
51	Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted. <i>Blood Advances</i> , 2021, 5, 3309-3321.	2.5	26
52	High-Risk Human Papillomavirus E6 Protein Promotes Reprogramming of Fanconi Anemia Patient Cells through Repression of p53 but Does Not Allow for Sustained Growth of Induced Pluripotent Stem Cells. <i>Journal of Virology</i> , 2014, 88, 11315-11326.	1.5	25
53	Peripheral Blood CD38 Bright CD8+ Effector Memory T Cells Predict Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1215-1222.	2.0	25
54	Poor Adherence Is Associated with More Infections after Pediatric Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 381-385.	2.0	25

#	ARTICLE	IF	CITATIONS
55	Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1273-1277.	2.0	24
56	Impaired immune function in children and adults with Fanconi anemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26599.	0.8	24
57	Comparing a Neutropenic Diet to a Food Safety-Based Diet in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1382-1386.	2.0	24
58	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
59	Oral Human Papillomavirus Is Common in Individuals with Fanconi Anemia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 864-872.	1.1	23
60	Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients. <i>Transfusion</i> , 2016, 56, 1402-1405.	0.8	23
61	Gene Therapy for Sickle Cell Anemia Using a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant Shows Promising Correction of the Disease Phenotype. <i>Blood</i> , 2018, 132, 1021-1021.	0.6	23
62	Hematologic complications with age in Shwachman-Diamond syndrome. <i>Blood Advances</i> , 2022, 6, 297-306.	2.5	23
63	A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2011-2018.	2.0	22
64	Xenon-129 MRI detects ventilation deficits in paediatric stem cell transplant patients unable to perform spirometry. <i>European Respiratory Journal</i> , 2019, 53, 1801779.	3.1	22
65	Hemophagocytic lymphohistiocytosis in a female patient due to a heterozygous <i>XIAP</i> mutation and skewed X chromosome inactivation. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1288-1290.	0.8	21
66	Reduction in Nephrotoxic Antimicrobial Exposure Decreases Associated Acute Kidney Injury in Pediatric Hematopoietic Stem Cell Transplant Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1654-1658.	2.0	20
67	Risk of Human Papillomavirus Infection in Cancer-Prone Individuals: What We Know. <i>Viruses</i> , 2018, 10, 47.	1.5	19
68	Feasibility of continuous temperature monitoring in pediatric immunocompromised patients: A pilot study. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27723.	0.8	19
69	Screening for Family Psychosocial Risk in Pediatric Hematopoietic Stem Cell Transplantation with the Psychosocial Assessment Tool. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1374-1381.	2.0	19
70	Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. <i>Blood Advances</i> , 2020, 4, 5745-5754.	2.5	19
71	Predictors of health-related quality of life over time among pediatric hematopoietic stem cell transplant recipients. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1834-1839.	0.8	18
72	A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2220-2225.	2.0	18

#	ARTICLE	IF	CITATIONS
73	CD38 ^{bright} CD8 ⁺ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1-6.	2.0	18
74	Incidence and Outcomes of Central Nervous System Hemophagocytic Lymphohistiocytosis Relapse after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 857-860.	2.0	17
75	BK polyomavirus diversity—Why viral variation matters. <i>Reviews in Medical Virology</i> , 2020, 30, e2102.	3.9	17
76	Successful use of whole genome amplified DNA from multiple source types for high-density Illumina SNP microarrays. <i>BMC Genomics</i> , 2018, 19, 182.	1.2	16
77	Long-Term Neurocognitive and Psychosocial Outcomes After Acute Myeloid Leukemia: A Childhood Cancer Survivor Study Report. <i>Journal of the National Cancer Institute</i> , 2021, 113, 481-495.	3.0	16
78	Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepea. <i>Transplantation</i> , 2021, 105, 891-896.	0.5	14
79	Increasing Activities of Daily Living Is as Easy as 1-2-3. <i>Journal of Pediatric Oncology Nursing</i> , 2016, 33, 345-352.	1.5	13
80	Team-based approach to identify cardiac toxicity in critically ill hematopoietic stem cell transplant recipients. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26513.	0.8	13
81	Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1523-1530.	2.0	13
82	Post-Transplant CD34 ⁺ Selected Stem Cell “Boost” for Mixed Chimerism after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Children and Young Adults with Primary Immune Deficiencies. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1527-1529.	2.0	13
83	Experience with a Reduced Toxicity Allogeneic Transplant Regimen for Non-CGD Primary Immune Deficiencies Requiring Myeloablation. <i>Journal of Clinical Immunology</i> , 2021, 41, 89-98.	2.0	13
84	Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant. <i>Blood Advances</i> , 2022, 6, 2897-2907.	2.5	13
85	GST genotype may modify clinical phenotype in patients with Fanconi anaemia. <i>British Journal of Haematology</i> , 2005, 131, 118-122.	1.2	12
86	A Pilot Study of Human Milk to Reduce Intestinal Inflammation After Bone Marrow Transplant. <i>Breastfeeding Medicine</i> , 2019, 14, 193-202.	0.8	12
87	Chimeric antigen receptor T cell therapy in patients with neurologic comorbidities. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28199.	0.8	12
88	Sleep disruption in caregivers of pediatric stem cell recipients. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26965.	0.8	11
89	Islam, The Holy Qur’an, and Medical Decision-Making: The Experience of Middle Eastern Muslim Families with Children Undergoing Bone Marrow Transplantation in the United States. <i>The Journal of Pastoral Care & Counseling: JPCC</i> , 2018, 72, 180-189.	0.4	11
90	Acute Kidney Injury in Children after Hematopoietic Cell Transplantation Is Associated with Elevated Urine CXCL10 and CXCL9. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1266-1272.	2.0	11

#	ARTICLE	IF	CITATIONS
91	Ruxolitinib for the Treatment of Chronic GVHD and Overlap Syndrome in Children and Young Adults. <i>Transplantation</i> , 2022, 106, 412-419.	0.5	11
92	Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation Recipients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 116.e1-116.e7.	0.6	11
93	Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 392.e1-392.e9.	0.6	11
94	Ibrutinib for the treatment of chronic graft-versus-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience. <i>Pediatric Transplantation</i> , 2020, 24, e13692.	0.5	10
95	Inherited DNA Repair Defects Disrupt the Structure and Function of Human Skin. <i>Cell Stem Cell</i> , 2021, 28, 424-435.e6.	5.2	10
96	Antibodies to BK virus in children prior to allogeneic hematopoietic cell transplant. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1670-1673.	0.8	9
97	Abnormal circumferential strain measured by echocardiography is present in patients with Shwachman's "Diamond syndrome despite normal shortening fraction. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1228-1231.	0.8	9
98	Combination of High-Dose Methylprednisolone and Defibrotide for Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 91-95.	2.0	9
99	$\alpha 4\beta 7$ Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28968.	0.8	9
100	Hematopoietic stem cell transplant for erythropoietic porphyrias in pediatric patients. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29231.	0.8	9
101	Pediatric Acute Lymphoblastic Leukemia: Is There Still a Role for Transplant?. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 363-367.	0.9	8
102	A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1829-1835.	2.0	8
103	Longitudinal examination of family efficacy following pediatric stem cell transplant. <i>Psycho-Oncology</i> , 2018, 27, 1915-1921.	1.0	8
104	A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 712-717.	2.0	8
105	Improving Oral Health and Modulating the Oral Microbiome to Reduce Bloodstream Infections from Oral Organisms in Pediatric and Young Adult Hematopoietic Stem Cell Transplantation Recipients: A Randomized Controlled Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1704-1710.	2.0	8
106	Endothelial injury, F-actin and vitamin-D binding protein after hematopoietic stem cell transplant and association with clinical outcomes. <i>Haematologica</i> , 2021, 106, 1321-1329.	1.7	8
107	Oral health and hematopoietic stem cell transplantation: A longitudinal evaluation of the first 28 days. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26773.	0.8	7
108	Interleukin-22 levels are increased in gastrointestinal graft-versus-host disease in children. <i>Haematologica</i> , 2018, 103, e480-e482.	1.7	7

#	ARTICLE	IF	CITATIONS
109	Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2416-2421.	2.0	7
110	Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series. <i>British Journal of Haematology</i> , 2021, 194, e84-e89.	1.2	7
111	Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531. <i>Blood</i> , 2010, 116, 182-182.	0.6	7
112	The impact of pediatric blood and marrow transplant on parents: introduction of the parent impact scale. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 46.	1.0	6
113	Rapid rituximab infusion is safe in paediatric and young adult patients with non-malignant indications. <i>British Journal of Haematology</i> , 2016, 173, 480-481.	1.2	6
114	Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1651-1658.	1.3	6
115	CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study. <i>Bone Marrow Transplantation</i> , 2020, 55, 1552-1559.	1.3	6
116	Comparison of the clinical phenotype and haematological course of siblings with Fanconi anaemia. <i>British Journal of Haematology</i> , 2021, 193, 971-975.	1.2	6
117	Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults. <i>Blood Advances</i> , 2022, 6, 1342-1349.	2.5	6
118	Safety and Efficacy of Prophylactic Levofloxacin in Pediatric and Adult Hematopoietic Stem Cell Transplantation Patients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 167.e1-167.e5.	0.6	6
119	Topical vitamin D analog for chronic graft versus host disease of the skin. <i>Bone Marrow Transplantation</i> , 2018, 53, 628-633.	1.3	5
120	Token economy to improve adherence to activities of daily living. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27387.	0.8	5
121	Multiple bloodstream infections in pediatric stem cell transplant recipients: A case series. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27388.	0.8	5
122	Quality Improvement Initiative to Reduce Nighttime Noise in a Transplantation and Cellular Therapy Unit. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1844-1850.	2.0	5
123	Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy. <i>Blood Advances</i> , 2020, 4, 3252-3257.	2.5	5
124	Longitudinal characterization of olfactomedin-4 expressing neutrophils in pediatric patients undergoing bone marrow transplantation. <i>PLoS ONE</i> , 2020, 15, e0233738.	1.1	5
125	Repolarization of HSC attenuates HSCs failure in Shwachman-Diamond syndrome. <i>Leukemia</i> , 2021, 35, 1751-1762.	3.3	5
126	Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 115-127.	1.1	5

#	ARTICLE	IF	CITATIONS
127	A prospective pilot study of a novel alemtuzumab target concentration intervention strategy. Bone Marrow Transplantation, 2021, 56, 3029-3031.	1.3	5
128	Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure. Blood Advances, 2021, 5, 4594-4604.	2.5	5
129	Accept the complement (blockade). Blood, 2017, 130, 842-843.	0.6	4
130	EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects. Pediatric Blood and Cancer, 2020, 67, e28126.	0.8	4
131	Incidence of thyroid dysfunction in children after HSCT with reduced intensity conditioning (RIC) or myeloablative conditioning (MAC). Pediatric Transplantation, 2021, 25, e13983.	0.5	4
132	Tryptophan metabolism is dysregulated in individuals with Fanconi anemia. Blood Advances, 2021, 5, 250-261.	2.5	4
133	Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531. Blood, 2011, 118, 939-939.	0.6	4
134	Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia. Vaccine, 2017, 35, 6712-6719.	1.7	3
135	Treatment exposures stratify need for echocardiographic screening in asymptomatic long-term survivors of hematopoietic stem cell transplantation. Cardiology in the Young, 2019, 29, 338-343.	0.4	3
136	Monitoring and treatment of MDS in genetically susceptible persons. Hematology American Society of Hematology Education Program, 2019, 2019, 105-109.	0.9	3
137	Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group. Clinical Cancer Research, 2020, 26, 2891-2897.	3.2	3
138	Pneumatosis intestinalis after hematopoietic stem cell transplantation: When not doing anything is good enough. Journal of Pediatric Surgery, 2021, 56, 2073-2077.	0.8	3
139	Human Papillomavirus Oral- and Sero- Positivity in Fanconi Anemia. Cancers, 2021, 13, 1368.	1.7	3
140	Testicular thrombotic microangiopathy: An unrecognized complication. Pediatric Blood and Cancer, 2021, 68, e29128.	0.8	3
141	Single-center results reporting improved hematopoietic stem cell mobilization success in pediatric and young adult patients with solid tumors and lymphoma. Pediatric Blood and Cancer, 2021, 68, e29319.	0.8	3
142	Rapid cardiac MRI protocol for cardiac assessment in paediatric and young adult patients undergoing haematopoietic stem cell transplant: a feasibility study. Cardiology in the Young, 2021, 31, 973-978.	0.4	3
143	Impact Of Residual Disease On Survival In Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation For Acute Myeloid Leukemia In First Complete Remission. Blood, 2013, 122, 65-65.	0.6	3
144	Acute myeloid leukemia in <i>SRP54</i> -mutated congenital neutropenia. EJHaem, 2022, 3, 521-525.	0.4	3

#	ARTICLE	IF	CITATIONS
145	BCG-osis and Hematopoietic Cell Transplant for Primary Immunodeficiencies. <i>Journal of Clinical Immunology</i> , 2021, 41, 491-494.	2.0	2
146	BK Polyomavirus Genotypes in Two Patients after Hematopoietic Cell Transplant. <i>Microbiology Resource Announcements</i> , 2021, 10, .	0.3	2
147	Psychometric evaluation of the brief RCOPE and relationships with psychological functioning among caregivers of children undergoing hematopoietic stem cell transplant. <i>Psycho-Oncology</i> , 2021, 30, 1457-1465.	1.0	2
148	Prospective pilot trial of calcipotriene as a novel topical treatment for acute skin graft versus host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1441-1444.	1.3	2
149	Optimized amplification of BK polyomavirus in urine. <i>Journal of Virological Methods</i> , 2022, 299, 114319.	1.0	2
150	Head and Neck Cancer Susceptibility and Metabolism in Fanconi Anemia. <i>Cancers</i> , 2022, 14, 2040.	1.7	2
151	Non-Tuberculous Mycobacterial Infection in Hematopoietic Cell Transplant. <i>Journal of Clinical Immunology</i> , 2020, 40, 1171-1175.	2.0	1
152	In response to "American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults". <i>Blood Advances</i> , 2020, 4, 5431-5432.	2.5	1
153	Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse " a Report From the Children's Oncology Group., <i>Blood</i> , 2011, 118, 3545-3545.	0.6	1
154	Variable Clinical Presentation of Shwachman-Diamond Syndrome: Update From the North-American Shwachman-Diamond Syndrome Registry.. <i>Blood</i> , 2012, 120, 2367-2367.	0.6	1
155	Abnormal Maximal and Submaximal Cardiopulmonary Exercise Capacity in Pediatric Stem Cell Transplant Recipients Despite Normal Standard Echocardiographic Parameters: A Pilot Study. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 263.e1-263.e5.	0.6	1
156	Who Evaluates and Counsels Related Donors?. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1526-1527.	2.0	0
157	Tribute: The American Society of Pediatric Hematology/Oncology (ASPHO), 2011 Distinguished Career Award goes to Dr. William G. Woods. <i>Pediatric Blood and Cancer</i> , 2011, 56, 895-896.	0.8	0
158	Making a little go a long way". <i>Blood</i> , 2015, 125, 2877-2878.	0.6	0
159	Human Milk to Prevent and Heal Gastrointestinal Tract Injury in Children After Bone Marrow Transplantation. <i>Breastfeeding Medicine</i> , 2018, 13, S-18-S-19.	0.8	0
160	Long-Term Survival and Late Deaths After Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism.. <i>Blood</i> , 2009, 114, 3320-3320.	0.6	0
161	Pathway Based Evaluation of Cytarabine Pharmacogenetics in Children with Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2610-2610.	0.6	0
162	Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531. <i>Blood</i> , 2010, 116, 2740-2740.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Oxidant Pathway Functional Polymorphisms Influence the Risk of Myeloid Leukemia/Transient Myeloproliferative Disorder In Children with Down Syndrome.. Blood, 2010, 116, 1680-1680.	0.6	0
164	Results of Allogeneic Hematopoietic Cell Transplantation in Persons with Fanconi Anemia and Pretransplant Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia. Blood, 2011, 118, 838-838.	0.6	0
165	Genetic Susceptibility Loci and Risk of Infant Leukemia by Subtype and MLL status: A Children's Oncology Group Report. Blood, 2011, 118, 749-749.	0.6	0
166	Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience. Blood, 2011, 118, 3074-3074.	0.6	0
167	Increased Oxidative Stress and Genomic Instability in Peripheral Blood and Bone Marrow of Individuals with Fanconi Anemia,. Blood, 2011, 118, 3425-3425.	0.6	0
168	Prenatal Origin of Monosomy 7 in Very Young Children.. Blood, 2012, 120, 2557-2557.	0.6	0
169	Deletion Of Fanca Or Fancd2 Dysregulates Treg Activity and Exacerbates Gvhd In Mice. Blood, 2013, 122, 3239-3239.	0.6	0
170	Influence of polymorphisms discovered in cell-based model of cytarabine sensitivity on outcome in pediatric AML: A Children's Oncology Group Study.. Journal of Clinical Oncology, 2014, 32, 10040-10040.	0.8	0
171	Inducible Loss of the Fanconi Anemia Pathway in iPSC Causes Rapid Cell Cycle Arrest and Apoptosis through ATM/ATR and p53 Signaling. Blood, 2014, 124, 3528-3528.	0.6	0
172	Germline and Somatic Genetic Characterization of Shwachman-Diamond Syndrome. Blood, 2016, 128, 2681-2681.	0.6	0
173	Reply to: Comment on: Hematopoietic stem cell transplant for erythropoietic porphyrias in pediatric patients. Pediatric Blood and Cancer, 2022, 69, e29432.	0.8	0
174	Grasping the sword of Damocles. Blood, 2021, 138, 1792-1793.	0.6	0
175	BK Polyomavirus Subtypes II and IV in Hematopoietic Cell Transplant Recipients. Microbiology Resource Announcements, 2022, 11, e0105321.	0.3	0
176	Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome. Blood, 2020, 136, 35-36.	0.6	0
177	Epidemiology of acute leukemia: what do we know and what do we need to learn?. Clinical Advances in Hematology and Oncology, 2003, 1, 339-40.	0.3	0